When it comes to venture funding, backing by corporate venture capitalists – whether solely or in a syndicate – is far better for biotech start-ups than merely receiving support from independent VCs, according to research by Wharton’s Mack Institute for Innovation Management. With their expansive access to experts, market resources, infrastructure and other assets, corporate VCs are twice as good as independent VCs in propelling a startup toward innovation success.
Gary Dushnitsky, a senior fellow at the institute and a…
